Vitrolife (VITR.ST) Osake Kurssi

Vitrolife AB is primarily active in the field of life sciences and reproductive medicine. As a leading biotechnology company, Vitrolife specializes in providing innovative solutions for fertility treatment and research. With its range of products and services, Vitrolife supports assisted reproductive technology (ART) procedures such as in vitro fertilization (IVF) and preimplantation genetic testing (PGT). The company's expertise and dedication to advancing reproductive medicine have made Vitrolife a trusted partner for clinics, researchers, and patients worldwide.

The main competitors of Vitrolife AB in the market include other leading companies in the field of assisted reproductive technology, such as Cook Medical Inc., Irvine Scientific, and Origio A/S. These companies offer similar products and services, aiming to provide innovative solutions for fertility treatments. However, Vitrolife AB sets itself apart through its extensive product portfolio, strategic partnerships, and continuous investment in research and development. With its strong presence in the market, Vitrolife AB maintains a competitive edge and remains a trusted choice for healthcare professionals and patients seeking high-quality solutions in assisted reproduction.

Vitrolife AB is a leading global biotechnology company that specializes in developing, manufacturing, and marketing products for assisted reproduction. Established in 1994, Vitrolife has a rich history and a strong background in the field of reproductive medicine. The company's mission is to increase the success rates of in vitro fertilization (IVF) by offering innovative solutions and high-quality products to fertility clinics worldwide. With a dedicated team of experts and continuous research and development efforts, Vitrolife strives to improve the chances of pregnancy and ultimately contribute to the happiness of families around the globe.

Vitrolife AB, a leading biotechnology company, has achieved several significant milestones. Over the years, the company has made groundbreaking innovations in the field of assisted reproduction, helping countless individuals achieve their desire of starting a family. Vitrolife AB developed cutting-edge products and techniques like time-lapse incubation systems and sequential media, revolutionizing the success rates of in vitro fertilization (IVF) procedures. The company has also expanded its global presence, establishing a strong presence in key markets worldwide. As a result, Vitrolife AB continues to be recognized as an industry leader, driving advancements in assisted reproductive technology and providing hope for couples struggling with infertility.

Vitrolife AB is primarily present in several countries and regions worldwide. These include Europe, North America, Asia, and Australia. The company has established a strong presence in Europe, with operations and distribution networks in countries such as Sweden, Germany, France, and the United Kingdom. In North America, Vitrolife AB has a significant presence in the United States and Canada. The company also operates in various countries across Asia, including China, Japan, and India. Additionally, Vitrolife AB has expanded into the Australian market, further enhancing its global presence.

Vitrolife AB represents a strong commitment to driving innovation and advancing the field of assisted reproduction. The company's values revolve around ensuring patient safety and providing high-quality products and expertise. With a corporate philosophy focused on continuous improvement, Vitrolife AB strives to offer cutting-edge solutions that improve outcomes and enhance the chances of successful pregnancies. Through their comprehensive product portfolio, integrated workflow systems, and ongoing dedication to research and development, Vitrolife AB remains at the forefront of reproductive technology, empowering fertility clinics worldwide to achieve their goals and help individuals and couples achieve their dream of having a baby.

Analyytikot asettavat tällä hetkellä Vitrolife-osakkeelle keskimääräisen tavoitehinnan 163,20 SEK (mediaani: 163,20 SEK), mikä merkitsee +41,3 % viimeisimpään hintaan verrattuna. Konsensus perustuu 10 analyytikkoarvioon.

Vitrolife Analyytikkojen kursstavoitteet 2026

10 analyytikkoa arvioi tällä hetkellä Vitrolife-osaketta: 8 suosittaa ostoa, 2 pitoa ja 0 myyntiä. Vuodelle 2026 analyytikot odottavat Vitrolife-yhtiöltä 3,48 Mrd. SEK liikevaihtoa ja 4,25 SEK osakekohtaista tulosta.

Vitrolife Analyytikkojen kursstavoitteet 2026

Nykyisellä valuuttakurssilla Vitrolife-osake noteerataan hintaan 10,53 EUR (115,50 SEK).

Vitrolife-osake (VITR.ST) on listattuna 6 pörssissä, muun muassa: London (0YAY.L), Frankfurt (VTFN.F), München (VTFN.MU), Düsseldorf (VTFN.DU), Stockholm (VITR.ST).

Vitrolife AB is a leading provider of products and services for reproductive medicine. The company operates in three business areas, each specializing in in vitro fertilization, stem cells, and tissue transplantation. In the field of in vitro fertilization (IVF), Vitrolife offers a wide range of products and services tailored to the needs of fertility clinics and research institutions. These include soluble culture media that optimize the in vitro development of eggs, sperm, and embryos. The company also offers products for the cryopreservation of eggs and embryos, as well as devices for the accurate application of IVF technology. In the field of stem cells, Vitrolife offers specialized culture media and other products that optimize the production and treatment of stem cells. The company is a leader in the development and provision of high-quality culture media for stem cells, and has also developed a wide range of accessories and devices to support stem cell experiments and procedures. In the field of tissue transplantation, Vitrolife offers artificial body fluids and surgical transplantation products for various applications. The area also includes products for the expansion of tissue cultures and various molecular kits that have been specifically developed to provide greater benefit in tissue transplantation. Vitrolife's business model is based on a combination of research and development, production, distribution, and marketing of products and services tailored to the needs of research institutions and medical centers. The company operates in a global market, with the US being the largest individual market. Thanks to a strong local presence and a prominent international focus, Vitrolife can serve both small and large markets in all geographic regions, taking into account the specifics of each region through continuous development. Customers can rely on a high standard of quality, innovative and forward-thinking products, and effective, precise solutions that Vitrolife customizes and delivers to its customers. The company has an excellent reputation in the industry and is known for having a dedicated research and development department. Vitrolife continuously works on improving its products and services to provide the highest quality. Overall, Vitrolife is a stable, innovative company with a mature business model. The company is well-positioned to continue growing and strive for global market leadership in a rapidly expanding market with promising future prospects.

odotettu liikevaihto Vitrolife on 3,48 Mrd. SEK. Tämä luku perustuu nykyisiin talousarvoihin ja heijastaa yhtiön liiketoimintasuoritusta.

odotettu voitto Vitrolife on 575,93 M SEK. Nettovoitto kuvastaa yhtiön kannattavuutta kaikkien kulujen vähentämisen jälkeen.

Vitrolife:n hinta-voitto-suhde (P/E) on tällä hetkellä 27,16. P/E-suhde vertaa nykyistä osakekurssia osakekohtaiseen tulokseen ja auttaa sijoittajia arvioimaan Vitrolife-osakkeen arvostusta.

Vitrolife:n hinta-myynti-suhde (P/S) on tällä hetkellä 4,50. P/S-suhde vertaa markkina-arvoa vuosittaisiin tuloihin ja toimii Vitrolife-osakkeen arvostuskennuslukuna.

Vitrolife:n Eulpool-laatuscore on 3/10.

Vitrolife:n ISIN on SE0011205202. ISIN (International Securities Identification Number) on maailmanlaajuisesti ainutlaatuinen arvopaperin tunnus.

Vitrolife:n WKN on A2JLT3. WKN (Wertpapierkennnummer) on kuusinumeroinen saksalainen arvopaperin tunnus.

Vitrolife:n ticker on VITR.ST. Tämä pörssinoteeraus käytetään Vitrolife-osakkeiden kauppaan pörssissä.